Lincoln, Ne., USA – Celerion, a provider of innovative early clinical research solutions, announces the appointment of Bruce Morimoto as executive director of Applied Translational Medicine.[break]
Dr. Morimoto will also assume leadership for the External Studies Management and Clinical Monitoring Services teams. Dr. Morimoto comes to Celerion with more than 20 years of experience in the pharmaceutical and biotechnology industries as well as in contract research organizations (CRO).
Prior to joining Celerion, he was Vice President of Drug Development at Allon Therapeutics, where his focus was to manage their neurodegeneration and dementia therapeutic programs including preclinical, manufacturing and clinical development.
Dr. Morimoto also held positions at MDS Pharma Services, a full service CRO; Neuromed Technologies, a biotech company developing novel pain therapeutics; Phoenix International Life Sciences, a global CRO; and Amur Pharmaceuticals, a biopharmaceutical company focused on diabetes and drug delivery research.
Dr. Morimoto earned his doctorate in biochemistry from the University of California, Los Angeles (UCLA), completed post doctorate research - May 22, 2013, Lincoln, Ne., USA – Celerion, a provider of innovative early clinical research solutions, announces the appointment of Bruce Morimoto as executive director of Applied Translational Medicine.
Article continues below
]
Dr. Morimoto will also assume leadership for the External Studies Management and Clinical Monitoring Services teams. Dr. Morimoto comes to Celerion with more than 20 years of experience in the pharmaceutical and biotechnology industries as well as in contract research organizations (CRO).
Prior to joining Celerion, he was Vice President of Drug Development at Allon Therapeutics, where his focus was to manage their neurodegeneration and dementia therapeutic programs including preclinical, manufacturing and clinical development.
Dr. Morimoto also held positions at MDS Pharma Services, a full service CRO; Neuromed Technologies, a biotech company developing novel pain therapeutics; Phoenix International Life Sciences, a global CRO; and Amur Pharmaceuticals, a biopharmaceutical company focused on diabetes and drug delivery research. ■